Kinaset Therapeutics Launches with a $40M Series A Financing to Develop Novel Therapeutics for Respiratory Diseases and an Exclusive Global License Agreement with Vectura Group for KN-002 (VR588), a Novel Anti-Inflammatory
Amount Raised
$40 Million
Round Type
Series A
MedfieldHealthcareHealth CareDescription
Kinaset Therapeutics, Inc. (“Kinaset” or the “Company”), a newly-founded biopharmaceutical company, today announced a $40 million Series A financing with a blue-chip investor syndicate of 5AM Ventures, Atlas Venture, and Gimv. The Company also announced an exclusive global in-license and services agreement with Vectura Group plc (LSE: VEC) (“Vectura”) to develop and commercialize KN-002 (formerly known as VR588), a novel, inhaled small-molecule pan-JAK inhibitor, for the treatment of eosinophilic and non-eosinophilic severe asthma. A Phase 1/1b clinical trial in healthy volunteers and patients is poised to begin in the first half of 2021.
Quick answer
Kinaset Therapeutics raised $40 Million in a Series A round, dated November 30, 2020. Kinaset Therapeutics is based in Medfield, Massachusetts, United States.
- How much did Kinaset Therapeutics raise?
- Kinaset Therapeutics raised $40 Million in a Series A round on November 30, 2020.
- What does Kinaset Therapeutics do?
- Kinaset Therapeutics is a clinical-stage biotechnology company focused on developing novel respiratory therapies for patients with intractable diseases, combining an experienced team with a potentially best-in-class..
- Where is Kinaset Therapeutics based and how big is it?
- Kinaset Therapeutics is based in Medfield, Massachusetts, United States.
- Who are the decision-makers at Kinaset Therapeutics?
- Fundz holds 1 contact at Kinaset Therapeutics, including the Executive Officer, Director, Promoter. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Healthcare and Health Care around the same time
Companies in the same sectors as Kinaset Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Mantra Health, Inc. raised $500K (Seed) on January 14, 2021.
- Zevra Therapeutics, Inc. raised $31M on January 13, 2021.
- Sparrow Pharmaceuticals raised $1.1M (Seed) on January 13, 2021.
- BlossomHill Therapeutics raised $2M on January 11, 2021.
- Werewolf Therapeutics raised $72M (Series B) on January 7, 2021.
- Balanced Pharma raised $3.2M (Seed) on January 7, 2021.
Who to call at Kinaset Therapeutics, and when
A new round usually means Kinaset Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Kinaset Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Kinaset Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Kinaset Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Kinaset Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansKinaset Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.